Morphological and functional studies on microencapsulated human fetal pancreatic tissue

Area of Science:

• Biomedical Engineering
• Endocrinology
• Regenerative Medicine

Background:

• Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia.
• Current treatments for diabetes include insulin therapy and, in some cases, pancreatic transplantation.
• Fetal pancreatic tissue offers a potential source for cell-based therapies due to its regenerative capacity.

Purpose of the Study:

• To assess the viability and function of microencapsulated human fetal pancreatic tissue in culture.
• To determine the suitability of microencapsulated fetal pancreatic tissue for potential transplantation in diabetes treatment.

Main Methods:

• Human fetal pancreases (4-6 months gestation) were microencapsulated using alginate and poly-lysine.
• Microcapsules were cultured for 4-7 days before morphological and functional studies.
• Immunocytochemical staining, radioimmunoassay (RIA) for insulin and C-peptide, and amylase determination were performed.

Main Results:

• B-cells within microcapsules remained morphologically intact up to 48 days.
• Microencapsulated tissues demonstrated sustained insulin secretion for 25 days, comparable to non-encapsulated tissues.
• No exocrine function was detected, indicated by negative amylase levels.

Conclusions:

• Microencapsulated human fetal pancreatic tissue maintains viability in culture for over 25 days.
• The retained insulin secretion function suggests potential therapeutic applications.
• These findings support the use of microencapsulated fetal pancreatic tissue as a transplantable material for managing diabetes mellitus.